RxDoctor Payments Data

Marilyn Telen, MD

Anatomic Pathology & Clinical Pathology · Durham, NCNPI 1346399367

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (40.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Pfizer at 36.9% of the total. Among anatomic pathology & clinical pathology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,987in general payments, 2019–2025

Across 21 payments — averaging $1237.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$10K
  • CSL Behring$8K
  • Octapharma USA, Inc.$8K
  • Novo Nordisk$122
  • Terumo BCT, Inc.$114
$1,340,560in research payments, 2019–2025

Across 210 payments — averaging $6383.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Global Blood Therapeutics, Inc.$537K
  • Pfizer$469K
  • CSL Behring$271K
  • Novo Nordisk AS$64K

What the payments were for

  • Consulting fees$9,27236%
  • Speaking & faculty fees$10,54541%
  • Travel & lodging$5,46521%
  • Food & beverage$7053%

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer4$9,602
CSL Behring10$8,201
Octapharma USA, Inc.5$7,949
Novo Nordisk1$122
Terumo BCT, Inc.1$114

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,987 in reported general payments places this provider in the 95th percentile of 221 anatomic pathology & clinical pathology providers in North Carolina.

See all anatomic pathology & clinical pathology providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,626
Medicare patients
35
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other anatomic pathology & clinical pathology in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →